NF-κB constitutively expresses in human pancreatic cancer cells and has been implicated in pancreatic tumorigenesis. Evodiamine, a bioactive alkaloid has been shown to possess antioxidant, anti-inflammatory and antitumor properties. In the present study, the anti-pancreatic cancer potential of evodiamine have been evaluated. Evodiamine effectively inhibited growth and induced apoptosis in PANC-1 cells in a dose-dependent manner. SN50 (NF-κBp65 inhibitor) significantly increased the evodiamine-induced apoptotic cell death in PANC-1 cells, indicating that NF-κB is involved in evodiamine-induced apoptotic cell death. Furthermore, Western blot analysis showed that evodiamine inhibited the constitutive activation of NF-κBp65, decreased the expression of anti-apoptotic protein Bcl-2, increased the expression of pro-apoptotic protein Bax and cleaved caspase-3 in PANC-1 cells in a dose-dependent manner. The present study suggests that evodiamine induces apoptosis in PANC-1 cells via NF-κBp65 inhibition and apoptosis regulators modulation.DOI: http://dx.doi.org/10.3329/bjp.v8i1.12802 Bangladesh J Pharmacol 2013; 8: 8-14